These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A victory for global public health in the Indian Supreme Court. 't Hoen E J Public Health Policy; 2013 Aug; 34(3):370-4. PubMed ID: 23677206 [TBL] [Abstract][Full Text] [Related]
23. Novartis challenges India's drug patent laws in Supreme Court. Billingsley M BMJ; 2012 Feb; 344():e1279. PubMed ID: 22354594 [No Abstract] [Full Text] [Related]
24. India's patent ecosystem - encouraging strong patents or discouraging innovation? Harrison C Nat Rev Drug Discov; 2013 Oct; 12(10):732-3. PubMed ID: 24080690 [No Abstract] [Full Text] [Related]
25. India's new patent bill threatens generic industry. Ahmad K Lancet Infect Dis; 2005 May; 5(5):265. PubMed ID: 15889471 [No Abstract] [Full Text] [Related]
26. Drugmakers struggle with Indian patents. Cancer Discov; 2012 Dec; 2(12):OF5. PubMed ID: 23230206 [TBL] [Abstract][Full Text] [Related]
27. "To patent or not to patent? the case of Novartis' cancer drug Glivec in India". Gabble R; Kohler JC Global Health; 2014 Jan; 10():3. PubMed ID: 24393270 [TBL] [Abstract][Full Text] [Related]
28. Recent developments in health law. India's evolving patent laws and WTO obligations: the rejection of Abbott Laboratories' application for a new Kaletra patent. Chilton A J Law Med Ethics; 2011; 39(2):296-300. PubMed ID: 21710799 [No Abstract] [Full Text] [Related]
29. Intellectual property. Balancing innovation and access: patent challenges tip the scales. Higgins MJ; Graham SJ Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944 [No Abstract] [Full Text] [Related]
30. Patent dispute: Delhi High Court gives a boost to access to affordable medicines. Menghaney L Indian J Med Ethics; 2010; 7(2):97-100. PubMed ID: 20432882 [TBL] [Abstract][Full Text] [Related]
31. Impact of India's new patents law 2005: a physician's perspective. Lele RD J Assoc Physicians India; 2005 Aug; 53():671-5. PubMed ID: 16398073 [No Abstract] [Full Text] [Related]
32. Final hearings begin in epic legal battle over Novartis drug in India. Mudur G BMJ; 2012 Sep; 345():e6257. PubMed ID: 22991008 [No Abstract] [Full Text] [Related]
33. India: New patent law may restrict access to HIV/AIDS treatments. Cruess G HIV AIDS Policy Law Rev; 2005 Aug; 10(2):28-30. PubMed ID: 16365971 [TBL] [Abstract][Full Text] [Related]
34. Patents: a threat to innovation? Manocaran M Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557 [No Abstract] [Full Text] [Related]
35. Patent. Battle lines are drawn over generic AIDS drug. AIDS Policy Law; 2005 Aug; 20(16):6. PubMed ID: 16161208 [No Abstract] [Full Text] [Related]
36. Patent infringement. Generic HIV drugmaker's patent claim is time-barred. AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916 [No Abstract] [Full Text] [Related]
37. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime. Halliburton M Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158 [TBL] [Abstract][Full Text] [Related]
39. Bayer challenges India's first compulsory licence for generic version of cancer drug. Arie S BMJ; 2012 Sep; 345():e6015. PubMed ID: 22956561 [No Abstract] [Full Text] [Related]
40. India's patent laws and the multinational pharmaceutical industry. Srinivasan S; Bharadwaj K Natl Med J India; 2013; 26(3):128-32. PubMed ID: 24476157 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]